Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis

(2014) S.P. Menting et al.   BRITISH JOURNAL OF DERMATOLOGY

Dose-creep of Infliximab During Psoriasis Treatment: An Observational Study

(2013) C Mehren et al.   ACTA DERMATO-VENEREOLOGICA

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

(2013) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

(2013) A. López-Ferrer et al.   BRITISH JOURNAL OF DERMATOLOGY

One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

(2013) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

(2013) P.L. Mattei et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

(2012) M.H.A. Rustin   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

(2012) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

(2011) Kenneth Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab

(2010) M. Papoutsaki et al.   DERMATOLOGY

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

(2010) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

(2010) A. Clemmensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM